SCHEDULE OF ROLL FORWARD OF CONTINGENT SHARES (Details) - GBP (£) |
6 Months Ended | |
|---|---|---|
Jun. 30, 2026 |
Jun. 30, 2025 |
|
| Share-Based Payment Arrangement [Abstract] | ||
| Contingent shares, balance | 1,385,392 | 1,974,208 |
| Contingent shares, balance | 77,018 | 44,100 |
| Intrinsic value, balance | ||
| Contingent shares, balance | (219,069) | |
| Contingent shares, balance | (49,948) | (30,271) |
| Contingent shares, balance | (45) | (2,054) |
| Contingent shares, balance | 1,193,348 | 1,985,983 |
| Intrinsic value, balance | £ 7,937,953 | £ 43,373,869 |
| X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options redeemed in period. No definition available.
|
| X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options reversed in period. No definition available.
|
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|